For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Maxim Pharmaceuticals, Inc.

USPTO Granted Patents = 27

Trademarks = 1

Forward Citations = 162

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Svante Hermod Hermodsson (20 out of 20 patents)

Kristoffer Hellstrand (16 out of 16 patents)

Kurt R Gehlsen (14 out of 14 patents)

4. Casimir Antczak (3 out of 3 patents)

5. Wen-Lung Yeh (3 out of 3 patents)

6. Jeffry David McGolrick (3 out of 3 patents)

7. Michael Joseph Roth (3 out of 3 patents)

8. Mark Wrona (3 out of 3 patents)

9. Jan Urban Kristoffer Hellstrand (2 out of 2 patents)

10. Jan Urban Hellstrand (2 out of 2 patents)

11. Bo Svennerholm (1 out of 7 patents)

12. Lars Rymo (1 out of 8 patents)

13. Stig Jeansson (1 out of 8 patents)

14. Peter Horal (1 out of 8 patents)

15. Anders Vahlne (1 out of 8 patents)

27 patents: Sort by Forward Citations

1. 6893633 - Methods and compositions for promoting the maturation of monocytes (2005-05-17),

2. 6821510 - Methods and compositions for promoting the maturation of monocytes (2004-11-23),

3. 6790440 - Methods and compositions for promoting the maturation of monocytes (2004-09-14),

4. 6730692 - Treatment and prevention of reactive oxygen metabolite-mediated cellular damage (2004-05-04),

5. 6620942 - Synthesis of histamine dihydrochloride (2003-09-16),

6. 6613788 - Elevation of circulating blood histamine levels (2003-09-02),

7. 6531120 - Ophthalmic histamine compositions and uses thereof (2003-03-11),

8. 6528654 - Synthesis of histamine dihydrochloride (2003-03-04),

9. 6498181 - Synergistic tumorcidal response induced by histamine (2002-12-24),

10. 6462067 - Treatment and prevention of reactive oxygen metabolite-mediated cellular damage (2002-10-08),

11. 6407133 - Treatment and prevention of reactive oxygen metabolite-mediated cellular damage (2002-06-18),

12. 6403806 - Synthesis of histamine dihydrochloride (2002-06-11),

13. 6375946 - Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor (2002-04-23),

14. 6350785 - Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors (2002-02-26),

15. 6305380 - Method for treatment of cancer and infectious disease (2001-10-23),

Maxim Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on developing innovative therapies for various diseases. With a dedicated team of researchers and scientists, Maxim Pharmaceuticals strives to improve patient outcomes and bring new treatments to market. Their commitment to research and development has resulted in the creation of groundbreaking drugs and treatment options. Visit their website for more information on their products and ongoing research efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

27 Patents

#210 in San Diego, CA

#2,844 in California

#11,991 in US

#23,270 in the World

San Diego, CA, United States of America

Maxim Pharmaceuticals, Inc.

Forward Citations = 162

15 inventors:

Svante Hermod Hermodsson (20 out of 20 patents)

Kristoffer Hellstrand (16 out of 16 patents)

Kurt R Gehlsen (14 out of 14 patents)

4. Casimir Antczak (3 out of 3 patents)

5. Wen-Lung Yeh (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…